Matches in DBpedia 2016-04 for { ?s ?p "Rapastinel (INN) (code name GLYX-13) is an intravenously-administered, selective, weak partial agonist of the glycine site of the NMDA receptor (IA ≈ 25%) which is under development by Naurex as an adjunctive therapy for treatment-resistant depression. It is an amidated tetrapeptide (Thr-Pro-Pro-Thr-NH2) which rapidly crosses the blood-brain-barrier, but is not active orally. On March 3, 2014 the U.S."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Rapastinel comment "Rapastinel (INN) (code name GLYX-13) is an intravenously-administered, selective, weak partial agonist of the glycine site of the NMDA receptor (IA ≈ 25%) which is under development by Naurex as an adjunctive therapy for treatment-resistant depression. It is an amidated tetrapeptide (Thr-Pro-Pro-Thr-NH2) which rapidly crosses the blood-brain-barrier, but is not active orally. On March 3, 2014 the U.S.".
- Q5513673 comment "Rapastinel (INN) (code name GLYX-13) is an intravenously-administered, selective, weak partial agonist of the glycine site of the NMDA receptor (IA ≈ 25%) which is under development by Naurex as an adjunctive therapy for treatment-resistant depression. It is an amidated tetrapeptide (Thr-Pro-Pro-Thr-NH2) which rapidly crosses the blood-brain-barrier, but is not active orally. On March 3, 2014 the U.S.".